Revenue: As of FY2026 Q1, the actual value is USD 55.93 M, beating the estimate of USD 54.98 M.

EPS: As of FY2026 Q1, the actual value is USD -1.32, missing the estimate of USD -0.0697.

EBIT: As of FY2026 Q1, the actual value is USD -199.96 M.

Definitive Healthcare Corp. operates as a single reportable segment, with financial information reviewed on a consolidated basis for resource allocation and performance assessment .

Revenue

• Total Revenue: Decreased by - $3.3 million (6%) to $55.929 million for the three months ended March 31, 2026, compared to $59.191 million for the same period in 2025, primarily due to lower subscription revenue, partially offset by higher professional services revenue .
  • Subscription services: $53.571 million for the three months ended March 31, 2026, down from $57.311 million in the prior year .
  • Professional services: $2.358 million for the three months ended March 31, 2026, up from $1.880 million in the prior year .
  • Revenue attributable to existing customers: Decreased by - $4.3 million for the three months ended March 31, 2026, partially offset by a $1.0 million increase from new customers .

Operational Metrics

• Cost of Revenue: Decreased by - $1.2 million (7%) to $14.279 million for the three months ended March 31, 2026, compared to $15.431 million for the same period in 2025, mainly due to a - $1.2 million decrease in data subscription and collection costs and a - $0.4 million decrease in amortization expense, partially offset by increased hosting fees and revenue sharing costs .
  • Cost of revenue exclusive of amortization: $9.355 million for the three months ended March 31, 2026, compared to $10.141 million in 2025 .
  • Amortization (Cost of Revenue): $4.924 million for the three months ended March 31, 2026, compared to $5.290 million in 2025 .
• Gross Profit: $41.650 million for the three months ended March 31, 2026, compared to $43.760 million for the same period in 2025 .
• Operating Expenses: Increased by $14.4 million (6%) to $242.940 million for the three months ended March 31, 2026, compared to $228.546 million for the same period in 2025 .
  • Sales and marketing: Decreased by - $1.1 million for the three months ended March 31, 2026, primarily due to lower personnel costs from reduced headcount .
  • Product development: Decreased by - $2.8 million for the three months ended March 31, 2026, mainly due to lower personnel costs and increased capitalized labor and overhead .
  • General and administrative: Decreased by - $0.2 million for the three months ended March 31, 2026, driven by lower personnel costs, equity grants at lower stock prices, and reduced recruiting fees, partially offset by increased professional fees .
  • Depreciation and amortization (Operating Expenses): Decreased by - $0.2 million for the three months ended March 31, 2026, due to certain customer relationship intangible assets utilizing economic consumption amortization methods .
  • Transaction, integration, and restructuring expenses: - $0.765 million for the three months ended March 31, 2026, a decrease of - $2.0 million from $1.265 million in 2025, driven by a favorable settlement of a major data contract .
  • Goodwill impairment: $197.219 million for the three months ended March 31, 2026, compared to $176.531 million in 2025 .
• Loss from operations: - $201.290 million for the three months ended March 31, 2026, compared to - $184.786 million in 2025 .
• Net loss: - $192.354 million for the three months ended March 31, 2026, compared to - $155.093 million in 2025 .
• Adjusted Gross Profit: $45.219 million (81% of revenue) for the three months ended March 31, 2026, compared to $47.073 million (80% of revenue) for the same period in 2025 .
• Adjusted EBITDA: $15.326 million (27% of revenue) for the three months ended March 31, 2026, compared to $14.706 million (25% of revenue) for the same period in 2025 .

Cash Flow

• Net cash provided by operating activities: $11.564 million for the three months ended March 31, 2026, compared to $26.066 million for the same period in 2025 .
• Net cash used in investing activities: - $6.221 million for the three months ended March 31, 2026, compared to $83.545 million provided by investing activities in 2025, primarily due to - $12.5 million in purchases of short-term investments and - $3.2 million in purchases of property, equipment, and data assets .
• Net cash used in financing activities: - $10.876 million for the three months ended March 31, 2026, compared to - $109.706 million for the same period in 2025, including - $7.8 million in payments under the Tax Receivable Agreement (TRA), - $2.2 million in term loan repayments, and - $0.9 million for taxes related to net share settlement of equity awards .

Unique Metrics

• Customer Count: Approximately 2,260 total customers as of March 31, 2026, down from 2,475 as of March 31, 2025 .
• Enterprise Customer Accounts: Decreased by 17 to 495 customers as of March 31, 2026, compared to 512 customers as of March 31, 2025 .
• Current Remaining Performance Obligations (cRPO): $160.565 million as of March 31, 2026, compared to $165.087 million as of December 31, 2025 .
• Total Remaining Performance Obligations: $230.508 million as of March 31, 2026, compared to $240.455 million as of December 31, 2025 .

Future Outlook and Strategy

Definitive Healthcare Corp. expects its revenue to decline in 2026 compared to 2025 due to sales execution challenges and sustained macroeconomic headwinds . The company anticipates a decrease in gross profit margin in 2026 due to revenue declines, a largely fixed cost structure, and the non-repeat of one-time data contract renegotiation credits from 2025 . While slowing hiring, the company plans continued investments in sales and marketing, product development, automation, and AI for innovation and system optimization, and will evaluate strategic acquisitions and investments to expand its platform .